Phoebe Rich

Featured in: Favicon

jrheum.org Favicon

Articles

Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study

Jun 5, 2024 | digitalcommons.library.tmc.edu | Stephen K. Tyring |Phoebe Rich |Yayoi Tada |Stefan Beeck

INTRODUCTION: Atopic dermatitis (AD) is a heterogeneous disease, with involvement of the T-helper cell (Th) 2, Th22, and potentially Th17 pathways, supporting the use of interleukin (IL)-23 and IL-22 blockade in AD.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →